Amarantus Bioscience Holdings Inc (AMBS)

[sumotrader]

Yeah, it looks like the voucher is only applicable to tropical or pediatric diseases at this time.

However, partnering with a company that possesses one could attract further interest from Big Pharma and provide a great deal of leverage and value at the bargaining table.

A PRV carries an estimated value of $50-500 million to the right candidate, Gerald should consider a trip to Montreal.

Novartis has already used a PRV to expedite one of it's drugs to market adding hundreds of millions in additional value to shareholders.